Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRCA1/2 genetic testing in the community setting.
Chen WY, Garber JE, Higham S, Schneider KA, Davis KB, Deffenbaugh AM, Frank TS, Gelman RS, Li FP. Chen WY, et al. Among authors: garber je. J Clin Oncol. 2002 Nov 15;20(22):4485-92. doi: 10.1200/JCO.2002.08.147. J Clin Oncol. 2002. PMID: 12431973
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Burstein HJ, et al. Among authors: garber je. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):496-504. doi: 10.1016/j.ijrobp.2005.07.975. Epub 2005 Oct 21. Int J Radiat Oncol Biol Phys. 2006. PMID: 16243442 Clinical Trial.
Genetic/familial high-risk assessment: breast and ovarian.
Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN; National Comprehensive Cancer Network. Daly MB, et al. Among authors: garber je. J Natl Compr Canc Netw. 2006 Feb;4(2):156-76. doi: 10.6004/jnccn.2006.0016. J Natl Compr Canc Netw. 2006. PMID: 16451772 No abstract available.
Molecular definition of breast tumor heterogeneity.
Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Shipitsin M, et al. Among authors: garber je. Cancer Cell. 2007 Mar;11(3):259-73. doi: 10.1016/j.ccr.2007.01.013. Cancer Cell. 2007. PMID: 17349583 Free article.
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. Burstein HJ, et al. Among authors: garber je. Clin Cancer Res. 2008 Dec 1;14(23):7871-7. doi: 10.1158/1078-0432.CCR-08-0593. Clin Cancer Res. 2008. PMID: 19047116 Clinical Trial.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Silver DP, et al. Among authors: garber je. J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100965 Free PMC article.
Genetic/familial high-risk assessment: breast and ovarian.
Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN; National Comprehensive Cancer Network. Daly MB, et al. Among authors: garber je. J Natl Compr Canc Netw. 2010 May;8(5):562-94. doi: 10.6004/jnccn.2010.0043. J Natl Compr Canc Netw. 2010. PMID: 20495085 No abstract available.
Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE. Rath MG, et al. Among authors: garber je. Breast Cancer Res Treat. 2013 May;139(1):193-8. doi: 10.1007/s10549-012-2375-z. Epub 2013 Apr 12. Breast Cancer Res Treat. 2013. PMID: 23580068 Free PMC article.
375 results